Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
candidate, ANX005, a monoclonal antibody, in patients with Guillain-Barré syndrome (GBS). Per the data readout from the pivotal phase III study, treatment with a single infusion of the 30 mg/kg dose strength of ANX005 met the study's primary endpoint, achieving a highly statistically significant 2.4-fold improvement on the GBS-disability scale (GBS-DS) at week 8. Treatment with ANX005 30 mg/kg also showed improvement in key secondary endpoints compared with placebo, which includes early gains in muscle strength as measured by the Medical Research Council sum score at day 8 and week 8 and a median of 28 fewer days on artificial ventilation through week 26. Furthermore, a 31-day reduction in the median time to walk independently compared with placebo was also observed upon treatment with the candidate's 30 mg/kg dose in a prespecified analysis. Annexon stated that patients treated with ANX005 30 mg/kg showed signs of improvement sooner compared with placebo on all the above-ment
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Huntington's Disease Pipeline Research 2024: Insights About 20+ Companies and 25+ Pipeline Drugs - Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]Yahoo! Finance
- Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual MeetingGlobeNewswire
- Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual MeetingGlobeNewswire
ANNX
Earnings
- 5/13/24 - Beat
ANNX
Sec Filings
- 6/25/24 - Form 8-K
- 6/12/24 - Form 8-K
- 6/7/24 - Form 4
- ANNX's page on the SEC website